{"brief_title": "A Study of Nystatin in the Prevention of Fungal Infections of the Mouth in Patients With AIDS or AIDS-Related Syndromes", "brief_summary": "To determine a safe, effective, and convenient dosing schedule for nystatin pastilles in the prophylaxis of oral candidiasis in patients with AIDS or AIDS related syndromes (group III or IV, CDC classification)", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Nystatin", "criteria": "Inclusion Criteria Concurrent Medication: Allowed: - Experimental drugs (IND drugs) which are targeted specifically against the AIDS virus or which stimulate the immune system. - Systemic or oral antibiotics. Patients must have AIDS or AIDS-related syndromes (HIV infection: - Group III or IV, CDC classification) and not have been treated for oral candidiasis during the past year. - Patients can be entered into the study who have: - Other oral lesions due to Kaposi's sarcoma, herpes zoster, and herpes simplex. - A positive or negative oral culture for Candida. - Must be able to follow instructions regarding the use of a pastille. Exclusion Criteria Co-existing Condition: Patients with the following are excluded: - Oral lesions diagnostic of oral candidiasis or systemic candidiasis. - Suspected or proven candidal esophagitis. Patients with the following are excluded: - Oral lesions diagnostic of oral candidiasis or systemic candidiasis. - Receiving any effective antifungal agent orally or intravenously within 72 hours of study entry. - Not expected to survive for at least 6 months. - Unable to voluntarily maintain a pastille in the buccal cavity for approximately 20 minutes twice a day. - Known hypersensitivity to nystatin. - Suspected or proven candidal esophagitis. Prior Medication: Excluded within 72 hours of study entry: - Any oral or intravenous antifungal agent.", "gender": "All", "minimum_age": "12 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00002293.xml"}